For the first time, since 1999, FDA will approve a new weight loss drug called Qnexa.
On Wednesday morning medical experts voted to endorse Qnexa. Final say is on the Food and Drug Administration, but from the former experiences this is just a formal decision because FDA almost always follows recommended advices from its committees.
Qnexa — is a combination of the anticonvulsant drug topiramate and the appetite suppressant phentermine.
In a clinical trial involving 4,323 people, about 10% of the total body weight was lost in the first year of use. Many users also saw improvements in blood pressure.
Trials also found some side effects like increased heart rate and increased risk of birth defects in women who became pregnant while taking the drug.
More than 35% of American adults are obese, including about 5% who are morbidly obese, and an additional 33% are overweight, according to the Centers for Disease Control and Prevention in Atlanta.
If approved by the FDA, Qnexa would be targeted for people with a body mass index of 30 or above.
Filed Under: Health & Fitness